Oncolys BioPharma Inc. (4588.T)
JPY 530.0
(0.38%)
JPY 530.0
(0.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.93 Billion JPY | -68.72% |
| 2022 | -1.14 Billion JPY | 28.88% |
| 2021 | -1.61 Billion JPY | 22.89% |
| 2020 | -2.09 Billion JPY | -129.64% |
| 2019 | -912.34 Million JPY | 26.06% |
| 2018 | -1.23 Billion JPY | -13.12% |
| 2017 | -1.09 Billion JPY | -17.1% |
| 2016 | -931.39 Million JPY | -8.64% |
| 2015 | -857.29 Million JPY | -16.01% |
| 2014 | -738.99 Million JPY | -16.28% |
| 2013 | -635.55 Million JPY | -518.07% |
| 2012 | -102.82 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -364.23 Million JPY | 45.28% |
| 2024 Q2 | -390.63 Million JPY | -7.25% |
| 2023 Q4 | -665.66 Million JPY | -64.73% |
| 2023 FY | -1.93 Billion JPY | -68.72% |
| 2023 Q1 | -323.69 Million JPY | -3.19% |
| 2023 Q2 | -545.07 Million JPY | -68.39% |
| 2023 Q3 | -404.08 Million JPY | 25.87% |
| 2022 FY | -1.14 Billion JPY | 28.88% |
| 2022 Q2 | -241.6 Million JPY | 26.55% |
| 2022 Q1 | -328.96 Million JPY | 48.26% |
| 2022 Q4 | -313.68 Million JPY | -18.52% |
| 2022 Q3 | -264.67 Million JPY | -9.55% |
| 2021 Q3 | -328.81 Million JPY | -9.5% |
| 2021 Q4 | -635.76 Million JPY | -93.35% |
| 2021 Q1 | -350.56 Million JPY | 36.22% |
| 2021 Q2 | -300.29 Million JPY | 14.34% |
| 2021 FY | -1.61 Billion JPY | 22.89% |
| 2020 Q3 | -880.67 Million JPY | -132.54% |
| 2020 Q4 | -549.67 Million JPY | 37.58% |
| 2020 FY | -2.09 Billion JPY | -129.64% |
| 2020 Q2 | -378.71 Million JPY | -32.41% |
| 2020 Q1 | -286.02 Million JPY | 11.1% |
| 2019 FY | -912.34 Million JPY | 26.06% |
| 2019 Q1 | -360.18 Million JPY | -8.52% |
| 2019 Q3 | -317.14 Million JPY | -465.76% |
| 2019 Q2 | 86.7 Million JPY | 124.07% |
| 2019 Q4 | -321.72 Million JPY | -1.45% |
| 2018 Q3 | -260.12 Million JPY | 21.28% |
| 2018 Q4 | -331.89 Million JPY | -27.59% |
| 2018 Q2 | -330.43 Million JPY | -6.12% |
| 2018 FY | -1.23 Billion JPY | -13.12% |
| 2018 Q1 | -311.38 Million JPY | -0.01% |
| 2017 Q4 | -311.34 Million JPY | -19.43% |
| 2017 FY | -1.09 Billion JPY | -17.1% |
| 2017 Q1 | -242.54 Million JPY | -21.37% |
| 2017 Q2 | -276.11 Million JPY | -13.84% |
| 2017 Q3 | -260.69 Million JPY | 5.58% |
| 2016 Q4 | -199.84 Million JPY | 36.27% |
| 2016 Q3 | -313.58 Million JPY | -35.32% |
| 2016 Q1 | -186.22 Million JPY | 27.3% |
| 2016 FY | -931.39 Million JPY | -8.64% |
| 2016 Q2 | -231.74 Million JPY | -24.44% |
| 2015 Q1 | -204.67 Million JPY | 29.93% |
| 2015 FY | -857.29 Million JPY | -16.01% |
| 2015 Q4 | -256.16 Million JPY | -31.62% |
| 2015 Q3 | -194.62 Million JPY | 3.56% |
| 2015 Q2 | -201.82 Million JPY | 1.39% |
| 2014 FY | -738.99 Million JPY | -16.28% |
| 2014 Q2 | -181.21 Million JPY | -71.85% |
| 2014 Q3 | -160.21 Million JPY | 11.59% |
| 2014 Q4 | -292.11 Million JPY | -82.33% |
| 2014 Q1 | -105.45 Million JPY | 64.12% |
| 2013 FY | -635.55 Million JPY | -518.07% |
| 2013 Q4 | -293.92 Million JPY | 0.0% |
| 2012 FY | -102.82 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 604.819% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | -267.898% |
| GNI Group Ltd. | 8.09 Billion JPY | 123.949% |
| Linical Co., Ltd. | 338.26 Million JPY | 673.071% |
| Trans Genic Inc. | 4.08 Million JPY | 47554.223% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | -34.81% |
| Soiken Holdings Inc. | -662.2 Million JPY | -192.736% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 1503.138% |
| AnGes, Inc. | -7.43 Billion JPY | 73.936% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | -50.489% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 73.05% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 1138.333% |
| NanoCarrier Co., Ltd. | -780 Million JPY | -148.526% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | -68.142% |
| CanBas Co., Ltd. | -1.2 Billion JPY | -60.34% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | -138.611% |
| RaQualia Pharma Inc. | -323.66 Million JPY | -498.929% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | -58.892% |
| Kidswell Bio Corporation | -1.42 Billion JPY | -36.315% |
| PeptiDream Inc. | 3.03 Billion JPY | 163.854% |
| Ribomic Inc. | -1.02 Billion JPY | -89.263% |
| SanBio Company Limited | -2.64 Billion JPY | 26.683% |
| Healios K.K. | -3.82 Billion JPY | 49.294% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -65.956% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | -30.136% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | -35.617% |
| StemRIM | -2.02 Billion JPY | 4.129% |
| CellSource Co., Ltd. | 923.14 Million JPY | 309.99% |
| FunPep Company Limited | -933.41 Million JPY | -107.679% |
| Kringle Pharma, Inc. | -854.15 Million JPY | -126.951% |
| Stella Pharma Corporation | -763.74 Million JPY | -153.814% |
| TMS Co., Ltd. | -960.04 Million JPY | -101.919% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | -71.547% |
| Cuorips Inc. | -632.18 Million JPY | -206.637% |
| K Pharma,Inc. | 260.33 Million JPY | 844.634% |
| Takara Bio Inc. | 1.48 Billion JPY | 230.98% |
| ReproCELL Incorporated | -31.41 Million JPY | -6070.635% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 7448.946% |
| StemCell Institute Inc. | 310.98 Million JPY | 723.352% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 1453.998% |
| CellSeed Inc. | -846.53 Million JPY | -128.993% |